Related references
Note: Only part of the references are listed.Clinical Course and Outcome in Children With Acute Lymphoblastic Leukemia and Asparaginase-Associated Pancreatitis
Susan L. Kearney et al.
PEDIATRIC BLOOD & CANCER (2009)
Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia
Dan Douer et al.
BLOOD (2007)
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Albert Moghrabi et al.
BLOOD (2007)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
PEG-asparaginase (Oncaspar) 2500 U/m2 BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols
HJ Müller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
LB Silverman et al.
BLOOD (2001)
Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)
LB Silverman et al.
LEUKEMIA (2000)
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia
MH Woo et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
